Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

Table 3 Variance of continuous CTC-counts according to therapy response after four (q4) or ten cycles (q10) of docetaxel

Response	CTC-Detection	Radiographic evaluation				Clinical criteria
Response	CTC-Detection	q0^a	q1^a	q4	q10	q0^a	q1^a	q4	q10
non-PD	Median, Range	5	1	0	0	4.5	1	0	0
	Median, Range	0-225	0-85	0-115	0-73	0-97	0-38	0-29	0-71
	Patients, n=	25	25	25	17	24	24	24	14
PD	Median, Range	24	9.5	32	23	22	11	34	17
	Median, Range	4-97	1-58	3-358	0-36	4-225	1-85	3-358	0-73
	Patients, n=	8	8	8	6	9	9	9	9
Significance, p=		0.04	0.01	<0.001	0.03	0.03	0.004	<0.001	0.03

PD, progressive disease according to therapy response assessment at q4 or q10; q, cycle of docetaxel
^aCTC-variance was assessed as a function of objective response at q4

ISSN: 1471-2407